{
  "docId": "019de071-b6aa-745b-9366-85da01204b7f",
  "docSlug": "36e600bcc4f8cdbd41dc817cb6eec90e",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 91 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 19,
  "pageCount": 91,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b6aa-745b-9366-85da01204b7f/19",
  "deckHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f",
  "deckJsonHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f.json",
  "deckAnchorHref": "/decks/019de071-b6aa-745b-9366-85da01204b7f#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.05,
        "y": 0.67
      },
      "kind": "callout",
      "text": "Expect to make XIPERE™ available in the U.S. during the first quarter of 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fddbde18-2af2-4569-bebf-7f526754dd1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.58,
        "x": 0.36,
        "y": 0.375
      },
      "kind": "chart",
      "text": "XIPERE™ Met Primary Efficacy Endpoint in Phase 3 PEACHTREE Study",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83dc4769-3a46-4984-baaf-ee4b43af0b53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.67,
        "y": 0.14
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2afe5b66-5061-4fb5-ac10-863034872ecb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.05,
        "y": 0.47
      },
      "kind": "list",
      "text": "XIPERE™ Partnership: Developed in partnership with Clearside Biomedical, Inc. Bausch Health holds exclusive license for commercialization and development of XIPERE™ in the U.S. and Canada",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95e97d99-a370-4443-b63c-7436a84af756",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.25,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Massa, H., Pipis, S. Y., Adewoyin, T., Vergados, A., Patra, S., & Panos, G. D. (2019). Macular edema associated with non-infectious uveitis... 2. Best-corrected Visual Acuity (BCVA).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c575f13-cfd6-4eef-b31e-96261c24f33b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.145
      },
      "kind": "subtitle",
      "text": "First and only therapy available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e1e8ff2-4cf5-4ad0-8a9e-16bacb534b87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "XIPERE™: Approved by FDA and Expected Launch 1Q22",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bf95110-5502-4c38-879c-79b6bc1225bd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 16,
      "beatId": "3301686e-d32a-433b-8780-603c1ac68052",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents growth initiatives and strategic alternatives",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "21cf5b4a-ca72-4285-ac92-38cb6528cb3d",
      "evidence": "The document highlights late-stage programs and recovery in progress",
      "position": 1,
      "objective": "Presenting growth initiatives",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}